Drugs / Measles, mumps, and rubella vaccine
Measles, mumps, and rubella vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05084508 Background | Feb 2022 → Feb 2024 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05084508 ↗ |
| Known as | M-M-R II | “MMR vaccine (M-M-R II or M-M-RVaxPro, depending on the country)” NCT05084508 ↗ |
| Known as | M-M-RVaxPro | “MMR vaccine (M-M-R II or M-M-RVaxPro, depending on the country)” NCT05084508 ↗ |
| Known as | MMR | “a measles, mumps, and rubella vaccine (MMR), a hepatitis A vaccine” NCT05084508 ↗ |
| Modality | Vaccine | “a measles, mumps, and rubella vaccine (MMR)” NCT05084508 ↗ |
| Route | Subcutaneous | “1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.” NCT05084508 ↗ |